Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Low Dose LSD: A Phase 1 Study
Neiloufar Family, Ph.D
We will be presenting the results of a recent Phase 1 double-blind, placebo-controlled, randomised trial that assessed the safety, tolerability, pharmacodynamics and pharmacokinetics of a 5 µg, 10 µg, and 20 µg LSD at 3-day intervals for 6 doses in healthy volunteers.
Neiloufar Family, Ph.D., is the Director of Clinical Research at Eleusis, with specific oversight over the firm's development of psychiatric therapeutics. She has overseen the planning, conduct, and analysis of two Phase 1 clinical trials investigating the therapeutic potential of LSD. Neiloufar previously did research on language and cognition as a post-doctoral fellow at the University of Kaiserslautern, and led a study on LSD’s effects on language in collaboration with Imperial College London.